We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $529M
1-Year Est. Return 337.4%
This Fund
S&P 500
This Quarter Est. Return
-8.59%
1 Year Est. Return
+337.4%
3 Year Est. Return
+710.06%
5 Year Est. Return
+1,177.67%
10 Year Est. Return
+20,064.24%
AUM
$233M
AUM Growth
+$8.01M
Cap. Flow
+$37.9M
Cap. Flow %
16.28%
Top 10 Hldgs %
54.5%
Holding
50
New
12
Increased
13
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$16.4M
2
ELGX
Endologix Inc
ELGX
+$10.9M
3
OCRX
Ocera Therapeutics, Inc.
OCRX
+$9.02M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$8.8M
5
CASC
Cascadian Therapeutics, Inc.
CASC
+$7.93M

Top Sells

Rank Stock Value
1
THOR
THORATEC CORPORATION
THOR
+$9.59M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$6.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$5.24M
4
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$4.25M
5
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$4.17M

Sector Composition

Rank Sector Weight
1 Healthcare 80.14%
2 Miscellaneous 19.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HPTX
1
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$20M 8.6%
793,864
+135,880
+21% +$3.37M
NBIX icon
2
Neurocrine Biosciences
NBIX
$15.2B
$18.2M 7.82%
1,161,739
-350,364
-23% -$5.24M
INFI
3
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$14.8M 6.34%
1,100,000
+141,400
+15% +$1.68M
ALIM
4
DELISTED
Alimera Sciences
ALIM
$14.2M 6.1%
174,657
+67,303
+63% +$5.75M
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$11.7M 5.02%
300,000
+49,900
+20% +$1.96M
ELGX
6
DELISTED
Endologix Inc
ELGX
$10.3M 4.43%
97,320
+77,992
+404% +$10.9M
DSCI
7
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$9.68M 4.16%
1,161,604
+13,312
+1% +$123K
ARDM
8
DELISTED
Aradigm Corp Common Stock
ARDM
$9.67M 4.15%
1,008,062
– –
AMBI
9
DELISTED
Ambit Biosciences Corp
AMBI
$9.24M 3.97%
600,000
-453,895
-43% -$3.12M
OCRX
10
DELISTED
Ocera Therapeutics, Inc.
OCRX
$9.11M 3.91%
1,859,315
+1,562,371
+526% +$9.02M
OFIX icon
11
Orthofix Medical
OFIX
$370M
$8.2M 3.52%
264,873
-35,827
-12% -$1.19M
AUPH icon
12
Aurinia Pharmaceuticals
AUPH
$2.15B
$7.92M 3.4%
+2,474,076
New +$8.8M
EXEL icon
13
Exelixis
EXEL
$14.1B
$7.8M 3.35%
+5,100,000
New +$16.4M
ARCT icon
14
CALL
Arcturus Therapeutics
ARCT
$450M
$7.52M 3.23%
+69,600
New +$9.07M
CASC
15
DELISTED
Cascadian Therapeutics, Inc.
CASC
$7.5M 3.22%
651,325
+519,358
+394% +$7.93M
FLNA
16
Filana Therapeutics
FLNA
$33.6M
$7.11M 3.05%
259,698
+17,661
+7% +$537K
VCEL icon
17
Vericel Corp
VCEL
$2.03B
$6.18M 2.66%
+2,170,000
New +$7.18M
EBS icon
18
Emergent Biosolutions
EBS
$326M
$6.18M 2.65%
+290,000
New +$6.64M
VCYT icon
19
Veracyte
VCYT
$3.23B
$5.92M 2.54%
607,296
+146,086
+32% +$1.92M
HTWR
20
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$5.43M 2.33%
+70,000
New +$5.8M
ACHV icon
21
Achieve Life Sciences
ACHV
$753M
$4.79M 2.06%
815
-145
-15% -$1.01M
SPHS
22
DELISTED
Sophiris Bio, Inc.
SPHS
$4.65M 2%
1,585,500
– –
TENX icon
23
Tenax Therapeutics
TENX
$68.5M
$4.38M 1.88%
35
-31
-47% -$3.98M
FRTX
24
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$3.39M 1.46%
960
+296
+45% +$1.15M
CUTR
25
DELISTED
Cutera, Inc.
CUTR
$3.18M 1.37%
315,000
+11,287
+4% +$112K
1
2

Similar funds

KMWM
Keudell/Morrison Wealth Management Salem, Oregon $529M AUM
FFIC
First Fiduciary Investment Counsel Cleveland, Ohio $529M AUM 15.02% 1-Year Est. Return
TA
Teramo Advisors Naples, Florida $529M AUM 20.59% 1-Year Est. Return
JDLA
J. Derek Lewis & Associates Newport Beach, California $529M AUM
CCG
Clearlake Capital Group Santa Monica, California $529M AUM 50.26% 1-Year Est. Return
DAS
DMKC Advisory Services Des Moines, Iowa $530M AUM 22.27% 1-Year Est. Return
VAMG
Voisard Asset Management Group Grand Rapids, Michigan $529M AUM 21.43% 1-Year Est. Return
CWM
Compass Wealth Management Guilford, Connecticut $528M AUM 40.26% 1-Year Est. Return

Great Point Partners's Q3 2014 Portfolio in Review

As of Q3 2014, Great Point Partners held 50 positions worth $233M, up 3.6% from $225M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Great Point Partners deployed $37.9M of net new capital in Q3 2014, opening 12 new positions and adding to 13 existing holdings. Its largest new stake was Exelixis: 5,100,000 shares worth $7.8M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 77% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was THORATEC CORPORATION, an estimated $9.59M trimmed.

  • Great Point Partners's largest Q3 2014 buy was Exelixis: 5,100,000 shares worth $7.8M.
  • Great Point Partners added most to Endologix Inc in Q3 2014, an estimated $10.9M increase.
  • Great Point Partners's biggest Q3 2014 reduction was THORATEC CORPORATION, cutting an estimated $9.59M.
  • Great Point Partners fully exited Arcturus Therapeutics in Q3 2014, selling an estimated $6.2M.
  • Great Point Partners's ten largest holdings make up 54% of its $233M portfolio in Q3 2014.
  • Great Point Partners opened 12 new positions and closed 12 in Q3 2014.
  • Great Point Partners's portfolio value rose 3.6% quarter-over-quarter to $233M.

Based on Great Point Partners's 13F filing for Q3 2014, filed 14 Nov 2014.